Your browser is no longer supported. Please, upgrade your browser.
Settings
ORPH [NASD]
Orphazyme A/S
Index- P/E- EPS (ttm)-3.98 Insider Own- Shs Outstand34.90M Perf Week-7.06%
Market Cap146.51M Forward P/E- EPS next Y-2.58 Insider Trans- Shs Float34.45M Perf Month-12.42%
Income-132.10M PEG- EPS next Q- Inst Own2.30% Short Float0.88% Perf Quarter-22.55%
Sales2.10M P/S69.76 EPS this Y-32.30% Inst Trans0.47% Short Ratio0.08 Perf Half Y-58.42%
Book/sh0.75 P/B5.27 EPS next Y- ROA-160.50% Target Price1.00 Perf Year-61.65%
Cash/sh1.41 P/C2.81 EPS next 5Y- ROE-251.20% 52W Range3.78 - 77.77 Perf YTD-63.19%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-94.92% Beta-
Dividend %- Quick Ratio1.80 Sales past 5Y- Gross Margin- 52W Low4.50% ATR0.32
Employees180 Current Ratio1.80 Sales Q/Q- Oper. Margin- RSI (14)43.04 Volatility5.36% 7.28%
OptionableYes Debt/Eq0.35 EPS Q/Q-61.80% Profit Margin- Rel Volume0.41 Prev Close4.12
ShortableYes LT Debt/Eq0.13 Earnings- Payout- Avg Volume3.74M Price3.95
Recom4.00 SMA20-4.47% SMA50-14.80% SMA200-51.15% Volume1,545,061 Change-4.13%
Jun-21-21Downgrade Guggenheim Buy → Sell
Mar-30-21Downgrade BofA Securities Neutral → Underperform $13 → $5
Oct-26-20Initiated Guggenheim Buy $27
Oct-26-20Initiated BofA Securities Buy $13
Oct-14-21 05:31AM  
Oct-07-21 02:40AM  
Oct-05-21 08:01AM  
02:55AM  
Sep-07-21 10:52AM  
10:18AM  
09:42AM  
Sep-06-21 12:38PM  
10:00AM  
09:15AM  
Sep-05-21 01:15PM  
04:00AM  
Sep-03-21 11:10AM  
11:00AM  
09:17AM  
Sep-02-21 02:25PM  
09:12AM  
Sep-01-21 12:49PM  
11:00AM  
08:59AM  
Aug-31-21 10:17PM  
04:35PM  
12:05PM  
01:00AM  
Aug-29-21 06:15PM  
05:10PM  
Aug-27-21 03:10PM  
Aug-26-21 11:35AM  
11:00AM  
Aug-25-21 08:36PM  
12:30PM  
08:33AM  
Aug-24-21 05:45PM  
08:00AM  
Aug-23-21 09:30AM  
05:04AM  
Aug-20-21 07:30PM  
Aug-19-21 02:23PM  
12:00PM  
11:55AM  
Aug-18-21 08:00PM  
Aug-17-21 07:06PM  
05:15PM  
11:00AM  
Aug-15-21 12:50PM  
Aug-14-21 10:30AM  
Aug-13-21 08:58PM  
12:30PM  
Aug-12-21 05:10PM  
11:00AM  
Aug-11-21 10:01PM  
08:00PM  
08:00PM  
08:34AM  
Aug-10-21 11:30AM  
Aug-09-21 07:30PM  
12:00PM  
Aug-07-21 03:00PM  
Aug-06-21 06:45PM  
Aug-05-21 06:54PM  
12:11PM  
11:30AM  
Aug-04-21 08:00PM  
11:05AM  
Aug-03-21 10:30PM  
04:04PM  
11:20AM  
10:00AM  
Aug-02-21 10:35PM  
Jul-30-21 07:40PM  
02:52PM  
Jul-29-21 12:30PM  
Jul-28-21 09:37PM  
08:33PM  
04:00PM  
11:00AM  
Jul-27-21 11:35AM  
11:00AM  
09:58AM  
08:00AM  
Jul-26-21 02:12PM  
01:00PM  
09:59AM  
Jul-25-21 11:20AM  
Jul-23-21 09:27PM  
10:15AM  
10:00AM  
Jul-22-21 12:30PM  
11:30AM  
10:14AM  
Jul-21-21 09:30PM  
08:00PM  
02:54PM  
02:00PM  
11:00AM  
10:13AM  
Jul-20-21 03:00PM  
02:04PM  
01:00PM  
10:12AM  
Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company focuses on the amplification of heat-shock proteins to develop and commercialize therapeutics for diseases caused by protein misfolding and aggregation, and lysosomal dysfunction, including lysosomal storage and neuromuscular degenerative diseases. Its lead candidate is the Arimoclomol, which is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Amyotrophic Lateral Sclerosis, Inclusion Body Myositis, and Gaucher disease. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark.